Kevin D’Amour, Ph.D., Chief Scientific Officer and VP, Research
San Diego, CA
ViaCyte is a privately-held clinical stage, regenerative medicine company developing novel stem cell-derived cell replacement therapies, with initial focus on developing products with the potential to provide a functional cure for Type 1 Diabetes (T1D). ViaCyte’s three product candidates utilize proprietary stem cell-derived pancreatic progenitor cells, which are implanted under the skin in durable cell delivery devices. The pancreatic cells are expected to mature and secrete insulin and other endocrine hormones in response to blood glucose levels. PEC-Direct is being developed for high-risk T1D patients with hypoglycemia unawareness, severe hypoglycemic episodes, and minimal to no insulin-producing beta cell function; it requires chronic immunosuppression. PEC-Encap expands the indication to all T1D patients, delivering pancreatic progenitor cells in an immunoprotective device. PEC-QT is being developed to expand usage to all T1D and T2D patients who require exogenous insulin by using cells specifically engineered to be immune-evasive to eliminate the need for immunosuppressants.

By using this website you agree to accept our Privacy Policy and Terms & Conditions